Showing results (201-210 of 235) with videos related to

Sort By:
Pageof 24
Breast (Edinburgh, Scotland)|April 8, 2016
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trialLukas Schwentner, Nadia Harbeck, Susanne Singer, et al.
Spine|September 1, 1996
The BWM spinal fixator system. A preliminary report of a 2-year prospective, international multicenter study in a range of indications requiring surgical intervention for bone grafting and pedicle screw fixationS I Bailey, P Bartolozzi, R Bertagnoli, et al.
Plos One|September 9, 2025
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivorsTatjana Braun, Sophia Huesmann, Kerstin Pfister, et al.
Plos One|November 19, 2025
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapyKerstin Pfister, Thomas W P Friedl, Andreas Hartkopf, et al.
Breast Cancer Research and Treatment|June 23, 2018
Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatmentEmanuel C A Bauer, Fabienne Schochter, Peter Widschwendter, et al.
Biomed Research International|May 7, 2014
Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancerB A S Jaeger, J Jueckstock, U Andergassen, et al.
Translational Oncology|December 23, 2015
Estrogen Receptor and HER2 Status on Disseminated Tumor Cells and Primary Tumor in Patients with Early Breast CancerBernadette A S Jäger, Charlotte Finkenzeller, Carolin Bock, et al.
Cancers|August 26, 2022
Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A TrialElisabeth K Trapp, Peter A Fasching, Tanja Fehm, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2016
Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A TrialL Schröder, B Rack, H Sommer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 29, 2000
Role of CC chemokines (macrophage inflammatory protein-1 beta, monocyte chemoattractant protein-1, RANTES) in acute lung injury in ratsN M Bless, M Huber-Lang, R F Guo, et al.
Pageof 24